1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Poxel’s Pioglitazone Formulation Meets Key Endpoints In Phase II NASH Study

 
• By Joseph Haas

A version of the diabetes drug intended to reduce PPAR gamma activation shows hoped for benefits and safety in a Phase II study. Poxel will now choose to advance one of two mid-stage NASH candidates.

Tough choice
Poxel now must make a decision on which Phase II NASH drug to take forward • Source: Shutterstock

Cash-poor Poxel SA is drawing nearer to a key decision about which of its two mid-stage non-alcoholic steatohepatitis candidates to move into Phase III, but positive top-line data reported on 30 August from a Phase II study of PXL065, a proprietary candidate derived from established diabetes drug pioglitazone, appeared to further de-risk at least one of its options.

Poxel, which reported cash on hand of €16.1m (about $16.8m) at the end of the second quarter, is focusing on...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Prilenia, Ferrer Map Out Plans For Pridopidine In Huntington’s

 
• By Alaric DeArment

The companies announced the publication of Phase III data that they said provide rationale for moving forward in a confirmatory trial.

AC Immune Cuts Workforce As Key Parkinson’s Readout Nears

 
• By Andrew McConaghie

The Swiss neuroscience specialist has extended its cash runway into late 2027, but will still need positive readouts in the coming months, including for its wholly owned Parkinson’s candidate.

‘Attenuated’ Survival Benefit In Bemarituzumab Trial Delays Filing Plans

 
• By Alaric DeArment

Amgen and Zai Lab said the final analysis of the FORTITUDE-101 trial showed a decreased magnitude of OS benefit in first-line gastric cancer.

AL-S Pharma’s AP-101 Shows Efficacy In ALS Clinical Trial

 
• By Jessica Merrill

The Phase II study tested AP-101 safety and tolerability as the primary endpoint but showed “clinically meaningful” efficacy in exploratory endpoints.

More from R&D

Xoma On Its Royalty Model And Cleaning Up ‘Zombie’ Companies

 
• By Manas Mishra and Andrew McConaghie

Seizing an opportunity to buy out struggling 'zombie' biotechs, Xoma is helping to return investor cash and pick up potential bargain assets for itself. Its CEO and chief investment officer explained their approach to Scrip.

Sanofi Shares Slide Despite Amlitelimab Eczema Win

 
• By Kevin Grogan

The OX40 ligand-targeting drug’s efficacy is seen as light compared with existing therapies.

Zydus Beats Gilead, Ipsen On Cholangitis Primary Endpoint But Pruritus Data Is Key

 
• By Vibha Ravi

Zydus's saroglitazar beat both Gilead’s Livdelzi and Ipsen’s Iqirvo on biochemical response in topline results from a Phase IIb/III trial in primary biliary cholangitis, but subtle differences in definitions, data on pruritus or itching and other factors could be key to approval and adoption.